This is the authors' abstract. We don't add key points for this paper.
Pancreatic cancer (PC) represents a substantial public health burden. Pancreatic cancer patients have very low survival due to the difficulty of identifying cancers early when the tumour is localised to the site of origin and treatable. Recent progress has been made in identifying biomarkers for PC in the blood and urine, but these cannot be used for population-based screening as this would be prohibitively expensive and potentially harmful.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Malhotra et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: